Crossmark

Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis

Crossref DOI link: https://doi.org/10.1186/s12974-018-1334-y

Published Online: 2018-10-30

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Yeseul

Kim, Gayoung

Shin, Hyun-June

Hyun, Jae-Won

Kim, Su-Hyun

Lee, Eunjig

Kim, Ho Jin https://orcid.org/0000-0002-7916-7422
Funding

Funding for this research was provided by:

Ministry of Science, ICT (M3A9B6069339)

Korea Centers for Disease Control & Prevention (2014-E63004-01)
License Information

Text and Data Mining valid from 2018-10-30
More Information

Article History

Received: 29 April 2018

Accepted: 15 October 2018

First Online: 30 October 2018

Ethics approval and consent to participate

: The Institutional Review Board of NCC approved the present study, and written informed consent was obtained from all participants.

: Not applicable.

: Kim YS, Kim GY, Hyun JW, Kim SH, and Shin HJ report no conflicts of interest. Kim HJ has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Celltrion, Eisai, Genzyme, , MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB; received a grant from National Research Foundation of the Ministry of Science and ICT; and accepted research funding from Genzyme, Merck Serono, Teva-Handok, and UCB; serves on a steering committee for MedImmune; is a co-editor for the Multiple Sclerosis Journal—Experimental, Translational, and Clinical, and an associated editor for the Journal of Clinical Neurology.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.